CYP19A1 and breast cancer: Afterwards, non-steroidal aromatase inhibitor (letrozole only) was approved by NHSO in 2009 to be used nationwide for adjuvant therapy for node-positive hormone-receptor positive postmenopausal breast cancer patients.